Stock Events

Stock Events

Barinthus Biotherapeutics. 

$0.7400
11
-$0.00-0.01% Wednesday 13:30

Statistics

Day High
0.7629
Day Low
0.6421
52W High
1.83
52W Low
0.512
Volume
376,145
Avg. Volume
52,008
Mkt Cap
30.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13MayExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.62
-0.55
-0.47
-0.4
Expected EPS
-0.54
Actual EPS
-0.4

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-66.43MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRNS. It's not an investment recommendation.
Clover Health Investments
2
CLOV
Kiora Pharmaceuticals
2
KPRX
Milestone Scientific
2
MLSS

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.84B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, directly competing in the same therapeutic areas as Barinthus Biotherapeutics.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening diseases, overlapping with Barinthus Biotherapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.8B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions, similar to Barinthus Biotherapeutics.
AMGEN
AMGN
Mkt Cap208.49B
Amgen is a global biotechnology company that develops innovative human therapeutics, with a product portfolio that competes with Barinthus Biotherapeutics in several key areas.
Biogen
BIIB
Mkt Cap31.84B
Biogen focuses on neurology, autoimmune disorders, and rare diseases, competing with Barinthus Biotherapeutics in the biopharmaceutical sector.
Alnylam Pharmaceuticals
ALNY
Mkt Cap32.06B
Alnylam Pharmaceuticals works on RNAi therapeutics, a novel technology that competes with Barinthus Biotherapeutics' innovative approaches to drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.38B
BioMarin Pharmaceutical focuses on rare genetic diseases, competing with Barinthus Biotherapeutics in targeting niche and underserved medical conditions.
Novartis
NVS
Mkt Cap266.8B
Novartis is a large pharmaceutical company with a broad range of products that compete across several of Barinthus Biotherapeutics' key strategic areas.
Pfizer
PFE
Mkt Cap157.65B
Pfizer is a global pharmaceutical corporation with a diverse portfolio, including areas that overlap with the therapeutic focus of Barinthus Biotherapeutics.

About

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Show more...
CEO
William James Enright
Employees
14
Country
United States
ISIN
US91864C1071
WKN
000A3CN5Q

Listings

STU
DE
2AB.STU
MU
DE
2AB.MU
OTCM
US
BRNS
BOATS
BOATS
BRNS.BOATS

0 Comments

Share your thoughts

FAQ

What is Barinthus Biotherapeutics. stock price today?▼
The current price of BRNS is $0.74 USD — it has decreased by -0.01% in the past 24 hours. Watch Barinthus Biotherapeutics. stock price performance more closely on the chart.
What is Barinthus Biotherapeutics. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Barinthus Biotherapeutics. stocks are traded under the ticker BRNS.
Is Barinthus Biotherapeutics. stock price growing?▼
BRNS stock has risen by +0% compared to the previous week, the month change is a +12.12% rise, over the last year Barinthus Biotherapeutics. has showed a -38.84% decrease.
What is Barinthus Biotherapeutics. market cap?▼
Today Barinthus Biotherapeutics. has the market capitalization of 30.23M
What were Barinthus Biotherapeutics. earnings last quarter?▼
BRNS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.54 USD resulting in a +25.93% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Barinthus Biotherapeutics. revenue for the last year?▼
Barinthus Biotherapeutics. revenue for the last year amounts to 0 USD.
What is Barinthus Biotherapeutics. net income for the last year?▼
BRNS net income for the last year is -66.43M USD.
How many employees does Barinthus Biotherapeutics. have?▼
As of September 25, 2026, the company has 14 employees.
In which sector is Barinthus Biotherapeutics. located?▼
Barinthus Biotherapeutics. operates in the Health & Wellness sector.
When did Barinthus Biotherapeutics. complete a stock split?▼
Barinthus Biotherapeutics. has not had any recent stock splits.
Where is Barinthus Biotherapeutics. headquartered?▼
Barinthus Biotherapeutics. is headquartered in Germantown, United States.